FDA approves COVID booster shots of immunodeficiency prior to CDC meeting

In a decision announced late Thursday night, the US Food and Drug Administration amended the Emergency Use Authorization (EUA) for both the Pfizer-BioNTech COVID-19 and Modana COVID-19 vaccines.

This is because the Centers for Disease Control and Prevention’s Immunization Implementation Advisory Board will meet on Friday to discuss further clinical recommendations for immunocompromised individuals.

The FDA’s announcement applies to millions of Americans who are particularly vulnerable to organ transplants, certain cancers, or other disorders.

Similar recommendations are made in several other countries, including France and Israel.

Vaccines do not always give the same protection as other healthy people because it is difficult to restore the immune system suppressed by certain drugs or illnesses-and at least some small studies Suggests what, extra dose may be the solution.

“This action is to ensure better protection from our most vulnerable … COVID-19,” said Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, at the FDA. I said before the announcement.

Importantly, this decision applies only to this high-risk group, about 3% of adults in the United States. It’s not the beginning of booster doses for the general public.

Instead, health officials will consider additional doses of the first COVID-19 vaccine prescription in the event of weakened immunity. For example, France has encouraged such patients to take a third dose four weeks after the usual second injection since April.

Apart from this, U.S. health officials continue to closely monitor whether and when the average person’s immunity is weakened and everyone needs additional immunity, but for now. , Vaccines continue to provide strong protection to the general public.